Skip to main content
. 2024 Oct 2;25(19):10617. doi: 10.3390/ijms251910617

Table 3.

In vivo echocardiography parameters.

C (n = 8) D (n = 7) SV (n = 7) V (n = 9)
IVSd (mm) 1.91 ± 0.58 2.31 ± 0.38 1.83 ± 0.25 # 1.78 ± 0.25 ##
IVSId (mm/kg) 4.30 ± 1.37 6.94 ± 1.04 ** 5.64 ± 0.65 # 5.73 ± 1.13 #
LVIDd (mm) 5.49 ± 0.67 5.06 ± 0.91 5.21 ± 1.12 4.92 ± 0.50
LVIDId (mm/kg) 12.26 ± 1.55 15.33 ± 3.35 * 16.46 ± 5.39 15.84 ± 2.52
LVPWd (mm) 2.35 ± 1.90 2.20 ± 0.72 1.89 ± 0.29 2.01 ± 0.66
LVPWId (mm/kg) 5.05 ± 3.47 6.51 ± 1.65 5.82 ± 0.87 6.47 ± 2.30
IVSs (mm) 2.93 ± 0.83 2.76 ± 0.51 2.17 ± 0.45 # 2.17 ± 0.35 #
IVSIs (mm/kg) 6.50 ± 1.69 8.31 ± 1.65 6.76 ± 1.65 6.96 ± 1.37
LVIDs (mm) 3.01 ± 0.21 3.71 ± 0.51 ** 3.43 ± 0.78 3.10 ± 0.21 ##
LVIDIs (mm/kg) 6.75 ± 0.72 11.27 ± 2.20 **** 10.86 ± 3.80 9.96 ± 1.16
LVPWs (mm) 2.93 ± 0.49 2.80 ± 0.66 2.56 ± 0.54 2.79 ± 0.60
LVPWIs (mm/kg) 6.57 ± 1.36 8.33 ± 1.43 * 7.80 ± 1.09 9.00 ± 2.29
CO (mL/dk) 101.25 ± 39.07 52.86 ± 29.84 * 60.14 ± 28.64 51.11 ± 13.64
CI (mL/dk.g) 0.23 ± 0.09 0.16 ± 0.09 0.19 ± 0.11 0.16 ± 0.05
EF (%) 81.60 ± 4.20 57.27 ± 7.21 **** 69.56 ± 5.84 ## 72.69 ± 3.72 ####
FS (%) 45.01 ± 4.54 26.04 ± 4.60 **** 34.34 ± 4.31 ## 36.63 ± 3.11 ####

IVSd, interventricular septum thickness at end diastole; IVSId, interventricular septum thickness at end diastole index; LVIDd, left ventricular internal dimension at end diastole; LVIDId, left ventricular internal dimension at end diastole index; LVPWd, left ventricular posterior wall thickness at end diastole; LVPWd, left ventricular posterior wall thickness at end diastole index; IVSs, interventricular septum thickness at end systole; IVSIs, interventricular septum thickness at end systole index; LVIDs, left ventricular internal dimension at end systole; LVIDIs, left ventricular internal dimension at end systole index; LVPWs, left ventricular posterior wall thickness at end systole; LVPWIs, left ventricular posterior wall thickness at end systole index; CO, cardiac output; CI, cardiac index; % EF, ejection fraction; % FS, fractional shortening; C, Control (n = 8); D, Diabetic (n = 7); SV, Sacubitril/valsartan-treated diabetic (n = 7); and V, Valsartan-treated diabetic (n = 9). *, p < 0.05; **, p < 0.01; ****, p < 0.0001 compared to control. #, p < 0.05; ##, p < 0.01; ####, p < 0.001 compared to diabetic.